Male Breast Cancer: Case Studies and Literature Review

Abstract

Male breast cancer is a rare disease. In Tunisia, it represents 1% of all breast cancers and 1.6% of Male neoplasia. This work is a retrospective study about 5 male patients with breast cancer, treated in the department of medical oncology at Fattouma Bourguiba University Hospital of Monastir (Tunisia) during a period of 3 years from March 2013 to March 2016. Results showed that: invasive ductual carcinoma was the histological type found in all cases; the Her 2 neu was not overexpressed in all cases; hormone receptors were positive in all patients. Two patients had a locally advanced disease. Two patients were diagnosed with metastatic disease; pulmonary and bone metastases. Three patients who were diagnosed with no metastatic disease have had a mastectomy with Axillary lymph node dissection. Adjuvant chemotherapy was administered in two patients. Loco regional radiotherapy was performed in three patients. Tamoxifen-based hormone therapy was administered in three patients. Two patients were treated with palliative chemotherapy. One patient received two lines of chemotherapy with a global survival of 16 months, while the other received only one line of palliative chemotherapy with a global survival of 2 months. One patient received palliative hormone therapy type Tamoxifen with progression free survival of 7 months. Three patients who received curative treatments are in remission of their disease. To conclude male breast cancer is a rare disease with multiple and varied risk factors. It is similar in its clinical, histological and prognostic characteristics to breast cancer in women but also has different characteristics.

Double Trouble: A Synchronous Male Breast Intraductal Papillary Carcinoma with Prostatic Adenocarcinoma

“…With the advent of the genetic molecular technologies, more knowledge regarding role of genetic become available. Male with BRCA1/2 mutations are at increased risk of cancers of the prostate and breast [4,5]. BRCA2 mutation accounts for 4-20% of male breast cancer and its carriers have 80 to 100 times higher lifetime risk than in the general population [3,5].…”

“…Male with BRCA1/2 mutations are at increased risk of cancers of the prostate and breast [4,5]. BRCA2 mutation accounts for 4-20% of male breast cancer and its carriers have 80 to 100 times higher lifetime risk than in the general population [3,5]. Apart from genetic component, other risk factors include conditions that disproportion the estrogen to androgen ratio.…”

“…Apart from genetic component, other risk factors include conditions that disproportion the estrogen to androgen ratio. Examples in Klinefelter's syndrome, exogenous estrogen or testosterone use, obesity, abnormalities of testicular condition such as orchitis or epididymitis, testicular ectopia, infertility, finasteride usage or history of prostate cancer treated previously with estrogen, gynaecomastia (though the relationship is still poorly understood) [3,5].…”

“…Lesion usually central and eccentric thus nipple involvement is common [2,3,6]. Ultrasonography and mammography are imaging of choice in further assessing lesion in male breast cancer with the latter shows sensitivity and specificity of 92% and 90% [5]. In Mathew et al study, pathologic finding of mammogram includes masses that are in high density, spiculated and mostly subareolar or eccentric in location.…”

Câncer de mama em homens

“…Além disso, a quimioterapia é indicada na melhoria da qualidade de vida, taxa de sobrevivência e de resposta em pacientes com doença metastática. Já a hormonioterapia deve ser indicada somente nos casos em que os tumores apresentam resposta positiva para receptores hormonais 10,11 .…”